View Older Stories
-
FDA may add black box warning to Covid-19 vaccines, CNN says
-
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
-
FDA probe of alleged deaths tied to Covid shots includes adults
-
FDA Probe Of Alleged Deaths Tied To Covid Shots Includes Adults
-
Clear Street Reiterates Buy Rating on BioNTech (BNTX)
-
Shares of vaccine makers drop after FDA memo flags reports of child deaths
-
BioNTech exchange offer for CureVac expires December 3
-
BioNTech (BNTX) PT Raised to $140 at H.C. Wainwright
-
BioNTech (BNTX) PT Lowered to $116 at TD Cowen
-
BioNTech (BNTX) PT Lowered to $181 at Clear Street
-
BioNTech (BNTX) PT Raised to $145 at Citi
-
BioNTech SE (BNTX) Misses Q3 EPS by 22c; lifts guidance
-
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.
-
TD Cowen Reiterates Hold Rating on BioNTech (BNTX)
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
-
EU will still have 15% pharma tariff, not 100% - Bloomberg
-
Rfk Jr. Weighs Expansion Of Vaccine Injury Program: Adviser - Bloomberg
-
CDC Panel Votes Against Requiring Prescriptions For Covid Shots - Bloomberg
-
CDC Panel Votes To End Universal Recommendation For Covid Shots - Bloomberg
-
Kennedy To Change Childhood Vaccine Schedule In Sept: Monarez - Bloomberg
-
BioNTech SE (BNTX) call put ratio 1 call to 2.1 puts with a focus on September puts as share price down 8.1%
-
Pfizer, Moderna, BioNTech trade lower amid report of vaccine link to child deaths
-
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
-
Pfizer and BioNTech report positive data for LP.8.1 COVID vaccine
-
BMO Capital Reiterates Outperform Rating on BioNTech (BNTX)
-
Clear Street on BioNTech (BNTX): 'BNT323 Clears Low Bar in Breast Cancer, But Incremental Validation Welcome'
-
BioNTech and DualityBio drug meets primary endpoint in phase 3 trial
-
BioNTech (BNTX) PT Lowered to $136 at H.C. Wainwright
-
BioNTech (BNTX) PT Lowered to $150 at Wells Fargo
-
BioNTech (BNTX) PT Raised to $120 at TD Cowen
-
BioNTech (BNTX) PT Raised to $185 at Clear Street
-
BioNTech SE (BNTX) Misses Q2 EPS by 19c; reaffirms guidance
-
H.C. Wainwright Reiterates Buy Rating on BioNTech (BNTX)
-
BioNTech (BNTX) PT Lowered to $138 at H.C. Wainwright
-
BioNTech (BNTX) to Acquire CureVac (CVAC) in Public Exchange Offer
-
BMO Capital: ACIP Cuts a Broad Negative To the Vaccine Space
-
Kennedy Removing All Members Of CDC Panel Advising On Vaccines
-
BioNTech (BNTX) PT Raised to $145 at H.C. Wainwright
-
Oppenheimer Reiterates Perform Rating on BioNTech (BNTX)
-
BioNTech (BNTX) PT Raised to $155 at Truist Securities
-
BioNTech (BNTX) PT Raised to $181 at Clear Street on BMY Deal
-
UBS Reiterates Neutral Rating on BioNTech (BNTX)
-
JPMorgan Reiterates Neutral Rating on BioNTech (BNTX)
-
BioNTech soars 15% on cancer drug deal with Bristol Myers
-
BioNTech and Bristol Myers Squibb enter up to $11.1B cancer drug collaboration
-
Bristol-Myers Squibb (BMY) and Biontech (BNTX) enter up to $11.1B Cancer Deal
-
Goldman Sachs Starts BioNTech (BNTX) at Neutral
-
Citizens JMP shares updates on cancer treatment stocks
-
FDA Mandates Trials For Covid Boosters For Healthy Kids, Adults - NEJM

